期刊: ANNALS OF THE RHEUMATIC DISEASES, 2021; 80 (1)
Objectives Janus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it w......
期刊: ANNALS OF THE RHEUMATIC DISEASES, 2021; 80 (8)
Objective To unravel the dynamical trajectory and features of glucocorticoids (GC) tapering and discontinuation in patients with rheumatoid arthritis ......